Dr. Grais has served as a member of the Board of Directors of Ocera Therapeutics, Inc. since January 2008 and as President and Chief Executive Officer of Ocera Therapeutics, Inc. since June 2012. Prior to her employment by Ocera, Dr. Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. She currently serves on the Board of Directors of Arca Biopharma, Inc.
Dr. Aggarwal has served as Chief Business Officer of Ocera Therapeutics, Inc. since May 2014. Prior to joining Ocera, Dr. Aggarwal was a life sciences venture capital investor primarily focused on biopharmaceutical companies. He served as a managing director of Investor Growth Capital, Inc., a venture capital firm, and as a partner of Panorama Capital, a venture capital firm. Prior to that, he was an investor with JPMorgan Partners, LLC, KBL Healthcare Ventures and Wasserstein Perella & Co. Dr. Aggarwal served on the board of directors for several biotechnology and medical device companies including Alvine Pharmaceuticals, Auspex Pharmaceuticals, FlowCardia, Hyperion Therapeutics, NextWave Pharmaceuticals and Piramed. Dr. Aggarwal received his M.D. from Columbia University, College of Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University.
Mr. Byrnes has served as Vice President, Finance of Ocera Therapeutics, Inc. since June 2014. Prior to joining Ocera, Mr. Byrnes served as Corporate Controller of Maxygen, Inc., MAXY since March 2010. From June 2007 to March 2010, Mr. Byrnes worked for NeurogesX, Inc., NGSX, in financial roles of increasing responsibility, most recently as Director of Finance. From December 2002 to June 2007, Mr. Byrnes served as Finance and Accounting Manager for Lipid Sciences Inc., LIPD. Mr. Byrnes’ experience also includes a variety of finance and accounting roles from 1996 to 2002 at ADAC Labs (a Philips Medical Systems company) and Bay View Capital Corporation. Mr. Byrnes received a B.S.C. in Finance from Santa Clara University and an M.B.A. from California State University, Hayward.
Dr. Patni has served as Chief Development Officer of Ocera Therapeutics, Inc. since September 2014. Prior to joining Ocera, Dr. Patni served as Senior Vice President for Actelion US Pharmaceuticals starting in September 2010. Prior to his time at Actelion, Dr. Patni served as Life Cycle Leader (Product Head), Executive Director and Vice President at Roche Pharmaceuticals from January 2007 to September 2010. Prior to his tenure at Roche, he held leadership positions at Novartis Pharmaceuticals and Pfizer Pharmaceuticals. Dr. Patni earned his B.S. from the Sophie Davis School of Biomedical Education at the City University of New York’s accelerated BS/MD Program and received his M.D. from Mount Sinai School of Medicine.
Dr. Rousseau has served as Chief Medical and Development Officer and as a member of the Board of Directors of Ocera Therapeutics, Inc. since July 2013. He joined Ocera (formerly Tranzyme) as Chief Medical Officer in October 2011. From 2003 to 2010, he worked at Gilead Sciences, Inc. (NASDAQ: GILD) where he had most recently served as Therapeutic Area Head, Hepatic Diseases, and initially as Vice President, Clinical Development. During this time, when he also was head of Gilead's Durham, North Carolina facility, Dr. Rousseau oversaw the clinical development for several drugs which ultimately received global marketing approval. From 1997 to 2002, Dr. Rousseau was Chief Medical Officer of Triangle Pharmaceuticals until its acquisition by Gilead in 2003. He began his pharmaceutical industry career in 1993 at Wellcome Lab, followed by two years with Glaxo Wellcome (NYSE: GSK) from 1995-1997 serving as Medical Advisor. Dr. Rousseau holds a Doctorate of Medicine and a Degree of Epidemiology and Nosocomial Infections from the University of Paris 7, Paris, France. He also holds a Degree of Statistics from the University of Paris 6, Paris, France.
Ms. Tetlow has served as Chief Financial Officer of Ocera Therapeutics, Inc. since June 2014. Ms. Tetlow is a managing director of Danforth Advisors, LLC, a financial advisory firm, since April 2012. Between October 2011 and March 2012, Ms. Tetlow served as chief financial officer of Pathwork Diagnostics, Inc., a privately held, commercial stage molecular diagnostics company. Between June 2005 and October 2010, Ms. Tetlow served as chief financial officer of Cell Genesys, CEGE. Prior to Cell Genesys, Ms. Tetlow was a venture partner with Apax Partners in Menlo Park, California. From 1999 until 2004, Ms. Tetlow served as chief financial officer of diaDexus, Inc., and previously worked in positions of increasing responsibility with Genentech, Synergen, Terrapin and Reprogen. Ms. Tetlow earned a B.S. in Arts and Sciences from the University of Delaware (magna cum laude and Phi Beta Kappa) and an MBA from Stanford University.